logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

We do not dare invest in the stock market at a time when almost all the stocks, both large and small, are yo-yoing for unknown reasons. The positive criteria has all but vanished, leaving behind it unparalleled inflation that is...

Read More

February 14, 2022

0

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting 

Moderna to Host Investor Event Via Webcast Moderna, Inc. ( MRNA ) announced that three abstracts on mRNA-4157 ( V940 ), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology...

Read More

May 23, 2024

0

What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

Intellia Therapeutics Loses Technology Patent and Suffers a Selloff A selloff of Intellia Therapeutics ( NTLA ) stock occured when the U.S. Patent and trademark office ruled that CRISPR genome editing technology patent belongs to the Broad Institute. It's stating...

Read More

March 1, 2022

0

Ionis Pharmaceuticals Presented Positive Results from Two Late Studies of investigational Product Donidalorsen

Ionis Parmaceuticals Treating Hereditary Angioedema On May 31, 2024, Ionis Pharmaceuticals ( IONS ) announced positive results from two Phase 3 OASIS-HAE and OASIS plus studies of the firm’s Donidalorsen in patients with hereditary angioedema ( HAE ). Donidalorsen demonstrating...

Read More

June 3, 2024

0

What About Agenus?

Answering Questions and Our Opinion About Agenus We believe that Agenus' ( AGEN ) frozen stock price for several years has and will continue to move up based on the recent news regarding the firm's promising oncology products. That's in addition...

Read More

June 5, 2024

0

Gilead Sciences and Arcus Biosciences: Treating Gastrointestinal Cancers

Gilead Sciences and Arcus Biosciences in the NEWS Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) announced longer-term efficacy and safety results from Arm A1 of Phase 2 EDGE-Gastric study. The updated data demonstrate consistent objective response...

Read More

June 6, 2024

0

ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. ( HKEX: 01801 )(OTC: IVBXF )  announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-4 monoclo-nal antibody) in combination with sintilimab as neoadjuvant treatment of...

Read More

June 13, 2024

0

Arcturus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update and Hosts a Conference Call

Arcturus Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call Before listening to the Conference call, which is at 4.30 PM, we remind about Arcturus Therapeutics Holding's history, which we believe proves the firm creates novel, safe and far...

Read More

March 7, 2024

0

Broadcom Inc. Announces 2Q Fiscal Year 2024 Financial Results, Quarterly Dividend and Stock Split 10-1

Broadcom Inc Announcements What analysts heard from the Artificial Intelligence ( AI ) firm Broadcom Inc is promising and exciting news about the past and excellent expectations regarding the future. The Story The Artificial Intelligence Broadcom Inc. ( AVGO )...

Read More

June 14, 2024

0

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms 

Vertex Pharmaceuticals Statistically Significant Results From Vertex VX-548 for Acute Pain Vertex Pharmaceuticals ( VRTX ) announced positive results from two Phase 2 proof-of-concept ( POC ) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain...

Read More

March 31, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 58
  • 59
  • 60
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy